Clinical Trials Browser

Phase 3 × Recruiting × Pemetrexed × Clear all

NCT04267848 2026-05-27

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06096844 2026-05-27

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Phase 3 Recruiting

Lung Neoplasms

NCT07190248 2026-05-26

KANDLELIT-007

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06312137 2026-05-22

TroFuse-019

Phase 3 Recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06627647 2026-05-22

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

Phase 3 Recruiting

Non-squamous Non-small Cell Lung Cancer

NCT06561386 2026-05-20

RELATIVITY1093

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06119581 2026-05-19

SUNRAY-01

Phase 3 Recruiting

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT06452277 2026-05-18

SOHO-02

Phase 3 Recruiting

Advanced Non-small Cell Lung Cancer

NCT06623422 2026-05-15

INTerpath-009

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06417814 2026-05-14

TROPION-Lung15

Phase 3 Recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT06875310 2026-05-13

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06793215 2026-05-11

Krascendo 2

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06632327 2026-05-08

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

Phase 3 Recruiting

Lung Neoplasms

NCT04585490 2026-05-04

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05624996 2026-05-04

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Phase 3 Recruiting

Lung Neoplasms

NCT06097728 2026-04-28

eVOLVE-Meso

Phase 3 Recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT07418749 2026-04-06

A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer

Phase 3 Recruiting

Uterine Cervical Neoplasms

NCT06687369 2026-03-11

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)

Phase 3 Recruiting

Non Squamous Non Small Cell Lung Cancer

NCT07174908 2026-03-03

A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06956001 2026-02-12

Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06970639 2026-02-12

A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

Phase 3 Recruiting

NSCLC Patients With Brain Metastasis

NCT06711900 2026-02-05

A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04339218 2026-01-30

CRYOMUNE

Phase 3 Recruiting

Adenocarcinoma of Lung

NCT06899126 2026-01-08

DESTINY-Lung06

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06908993 2025-12-17

COMET

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06927986 2025-11-17

Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07178795 2025-11-17

A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC

Phase 3 Recruiting

Non-squamous Non-small Cell Lung Cancer

NCT07050043 2025-07-03

LEDANG

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05692999 2025-06-25

Pulse

Phase 3 Recruiting

Metastatic Non-squamous Lung Cancer

NCT06754644 2025-06-10

A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC

Phase 3 Recruiting

NSCLC

NCT06829459 2025-04-08

A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06416410 2025-04-04

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Phase 3 Recruiting

Advanced Non-squamous Non-small-cell Lung Cancer

NCT05487391 2024-10-15

A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05055908 2024-08-02

BECOME

Phase 3 Recruiting

12,000 enrolled

Lung Neoplasms

NCT05754853 2023-04-13

A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

Phase 3 Recruiting

Advanced or Metastatic Urothelium Cancer